References

  1. Sonis, S. T. (2004) Oral mucositis in cancer therapy. J Support Oncology, 2(3):3–8.

  2. Trotti, A., Bellm, L. A., Epstein, J. B., et al. (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol, 66(3):253–262.

  3. Wardley, A. M., Jayson, G. C., Swindell, R., et al. (2000) Prospective evaluation of OM in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol, 110(2):292–299.

  4. Fulton, J. S., Middleton, G. J., McPhail, J. T. (2002) Management of oral complications. Semin Oncol Nurs, 18(1):28–35.

  5. Dodd, M. J., Miaskowski, C., Dibble, S. L., et al. (2000) Factors influencing OM in patients receiving chemotherapy. Cancer Pract, 8(6):291–297.

  6. Elting et al. Costs of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future Study, JNCI Monographs. 2019, 2019(53):lgz010, https://doi.org/10.1093/jncimonographs/lgz010

  7. Elting et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007, 68(4):1110–1120.

  8. Sonis et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001, 19(8):2201–2205.

  9. Nomura et al. Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis. Ann Oncol. 2013, 24:1062–1066.

  10. Ellington et al. Trends in Incidence of Cancers of the Oral Cavity and Pharynx — United States 2007–2016. MMWR Morb Mortal Wkly Rep 2020;69:433–438. DOI: http://dx.doi.org/10.15585/mmwr.mm6915a1external icon.

  11. Elrefaey et al. HPV in oropharyngeal cancer: the basics to know in clinical practice Acta Otorhinolaryngol Ital. 2014 Oct; 34(5): 299–309.